By Robb M. Stewart
MELBOURNE, Australia--CSL Ltd.'s (CSL.AU) chief financial
officer is set to take the reins of the specialty biopharmaceutical
company's new influenza-vaccine business, which it aims to launch
at the start of next year.
Gordon Naylor, who has had executive-management responsibility
for the company's existing vaccines and pharmaceutical business
since 2012, will remain in his current role through a transition
period with his successor, CSL said Thursday. The company plans to
begin an international search for a new CFO shortly.
CSL's proposed new global influenza-vaccine unit will combine
its existing operation, bioCSL, and the influenza-vaccine business
bought from Novartis AG (NVS) last October for US$275 million. The
new vaccine-manufacturing business will have plants in the U.S.,
U.K., Germany and Australia.
Write to Robb M. Stewart at robb.stewart@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires